Introduction
The envelope proteins of human immunodeficiency virus type 1 (HIV-1) are synthesized as a 160K molecule which is subsequently cleaved to give molecules of 120K and 41K. The 41K molecule (gp41) exists in trimeric or tetrameric form in the membrane of the virion (Pinter et al., 1989) interacting non-covalently with the 120K molecule (gpl20) which is external to the virion. The weak association of the transmembrane molecule and the external glycoprotein leads to shedding of gp 120 from the virion soon after maturation, leaving the gp41 exposed on the virus surface (Kieny et al., 1986; Schneider et al., 1986; Gelderblom et al., 1989) . Antibodies recognizing gp41 are therefore potentially capable of interfering with virus infection.
Antibodies to gp41 may be important in protection, at least in the case of challenge with cell-free virions which have shed some of their gpl20. Antibodies alone, generated by inactivated whole virus, have been shown in simian models of AIDS to be protective against cellfree virus of the immunizing strain (Desrosiers et al., 1989; Murphey-Corb et al., 1989) . Protection between strains of HIV-1 may involve antibodies to gp41 since this molecule offers a candidate 'group-specific' neutralizing epitope (amino acids 735 to 752). Antibodies raised to this epitope neutralize a wide range of HIV-I strains (Dalgleish et al., 1988; Evans et al., 1989) . Moreover, it has not proved possible to absorb 'group-specific' neutralizing antibodies from the serum of HIV-seropositive individuals using gpl20 purified from virus-0000-9557 © 1990 SGM infected cells nor recombinant gp120 (Matthews et al., 1986; Steimer et al., 1988) .
Synthetic peptides have been used previously to identify the epitopes recognized by infected individuals within gp41 and the epitopes which induce neutralizing antibodies in experimental animals (Ho et al., 1987; Kennedy et al., 1986; Mathiesen et al., 1989b) . Unfortunately, these two groups of epitopes are not identical. The antibody response to a single epitope (amino acids 600 to 611) is predominant in HIV-seropositive humans and as yet no explanation has been available for this immunodominance (Gnann et al., 1987; Mathiesen et al., 1989a) . In this paper, an explanation is offered.
Methods
Peptides and conjugates. The amino acid sequences of the peptides follow that published by Sanchez-Pescador et al. (1985) starting at residue 531 of the envelope protein gp 160. The peptides have 15 amino acids of the published sequence and overlap by five amino acids. Thus, peptide env 54 has the sequence corresponding to amino acids 531 to 545, peptide env 55 the sequence 541 to 555, peptide env 56 551 to 565 and so on to give peptide env 86 with sequence 851 to the C terminus of gp41/gpl60 at amino acid 863. An additional cysteine has been added to the C terminus of most of the peptides to enable conjugation to a carrier protein, with some exceptions. Peptide env 61 has two cysteine residues internally so that a tyrosine is used as the additional amino acid. Either the N or the C terminus of peptides env 60, env 62, env 64, env 77 and env 78 coincides with a cysteine or tyrosine residue and no additional residue is required. Peptide env 86 has a cysteine residue added to the N terminus (Table 1) . The peptides were synthesized by the FMOC-polyamide method. Five mg of each peptide was retained by the manufacturers (Cambridge Research Biochemicals) for conju- 
gation to purified protein derivative (PPD) either through the terminal cysteine residue using m-maleimidobenzoic acid-N-hydroxysuccinimide ester or the terminal tyrosine residue using bis-diazotized tolidine.
Sera. Blood was obtained from 13 patients who were seropositive for HIV. Ten were in CDC Stage II, two in Stage III and a further one in Stage IV C2. The blood was allowed to clot and then centrifuged. The serum was removed and heat-inactivated at 56 °C for 30 min. Blood was also obtained from healthy laboratory personnel and similarly heat-inactivated. Ethical considerations prevent confirmation that these individuals are seronegative for HIV.
Injection schedules. F1 AO/LOU hybrid rats of either sex were injected intradermally with one human dose of BCG. Three weeks later the rats were injected with 100 ~tg of peptide conjugated to PPD precipitated with alum, together with 25 ~tg of colchicine. The injection was repeated at fortnightly intervals. Rats were bled from the tail 2 weeks after each injection of conjugate. The sera used in this study were taken after the third and fourth injections.
Solid phase anti-peptide radioimmunoassay. Peptides were weighed and dissolved in water to give stock solutions with a nominal concentration of 1 mg/ml. (The mass of counter ions included in the weighed material was unknown and peptides differed in their solubilities so that the mass of dissolved peptide is not known.) Stock solutions were stored at -20 °C. Solutions of peptide were prepared at 10 ~tg/ml in coating buffer (0.1 M-NaHCO3, 0.1 M-Na2CO 3 pH 9.6) and 50 ~tl was dispensed into wells on a 96-well Falcon microtest flexible plate. The plates were covered and incubated overnight at 4 °C in a water-saturated atmosphere.
Sera were diluted (1:500) in phosphate-buffered saline (PBS) with 2mg/ml (w/v) of bovine serum albumin, 0.05~ Tween 20 and 10 mi-azide. Plates were washed six times in this buffer and 50 ktl of diluted serum was dispensed. The plates were further incubated overnight at 4 °C in the wet box. The presence of antibodies in the wells after six washes with buffer was determined with afffinity-purified, 125I-radiolabelled antibodies to human IgG. The radiolabelled reagent was prepared using iodogen (Sigma) to give approxiamtely 3 ~tCi/ktg of antibody. It was microfuged immediately before use to remove aggregates. Plates were incubated overnight at 4 °C in the wet box. The plates were washed six times in buffer, individual wells were removed with a hot wire and residual radioactivity was determined. In competition assays sera were mixed with peptide at a final concentration of 10 ktg/ml and incubated overnight at 4 °C before dispensing into wells.
Radioimmunoassay for human IgG. A similar assay was used to measure the IgG content of affinity-purified antibodies. The solid phase was goat antibodies to human IgG and bound antibody was detected with 12SI-labelled antibodies to human IgG from the same source. A standard curve was prepared with Cohn fraction II human gammaglobulin (Sigma).
Affinity purification of antibody by cyanogen bromide-linked peptide.
Peptides were dissolved in 0.2 M-NaHCO 3 and conjugated to CL4B Sepharose (Pharmacia) with cyanogen bromide. CL4B Sepharose (2 ml) was treated with 100 ~tg of cyanogen bromide diluted in 2 M-Na2CO3 for 1 to 2 min and the resultant slurry was washed in a sintered glass funnel (No. 1) with 40 ml of 0.2 M-NaHCO3 (pH 9.5) followed by distilled water and a further wash with sodium bicarbonate. The dissolved peptide (1 to 1.5 mg in 2ml sodium bicarbonate) was added to the Sepharose and incubated overnight at 4 °C with continual mixing.
The CnBr-Sepharose was recovered with a sintered glass funnel (No. 1) and washed with 80 ml of (i) 0.1 M-sodium acetate pH 4 in 0.5 M-NaCI, (ii) 2 M-urea in 0"5 M-NaCI, (iii) 0"1 M-NaHCO3 pH 10 in 0.5 M-NaC1, (iv) PBS, (v) 1 M-NaC1, (vi) 4 M-MgC12, (vii) 1 M-NaCI and (viii) PBS. Columns were prepared with the CnBr-Sepharose and washed with 20 ml of PBS. Serum (0.5 to 1.0 ml) was added and allowed to incubate overnight at 4 °C. The serum was removed by washing the column through first with 10 ml of PBS and then with 20 ml of I M-NaC1. The antibody retained on the column was recovered using 4 M-MgC12 and immediately dialysed against two changes of 21 of 0.9 (w/v) NaC1 followed by dialysis against 21 of PBS.
In a single experiment, a control preparation of Sepharose was prepared by treating with CnBr and incubating overnight without peptide. The supernatant from this preparation was used as a blank for absorbance measurements in a u.v. spectrophotometer against the supernatant of an experimental preparation run in parallel using peptide env 67 to confirm that the concentration of peptide had been reduced following incubation with cyanogen bromide.
Affrnity purification by thiol-activated Sepharose-linked peptide.
Peptide env 60 (1.5 mg) was dissolved in PBS. Activated thiolSepharose 4B (1 g) was washed for 15 min in 200 ml of PBS on a sintered glass funnel (No. 1) and used to prepare two 2 ml columns. Peptide was circulated through one of these columns until the u.v. absorbance stabilized. Serum was added to both columns and left at 4 °C overnight. Both columns were subsequently flushed with 20 ml of PBS and antibody was recovered with glycine-HC1 pH 2.5. The second and third 1 ml fractions were immediately dialysed against three changes of 21 of PBS. program of Lipman & Pearson (1985) with a ktup of 1 and a cutoff of 40 was used. In this strategy, the peptide is aligned with a protein and each amino acid of the peptide is individually (hence ktup of 1) compared with its counterpart in the protein. Each comparison is scored.
Residues that are identical and that are found infrequently in proteins are given higher scores than identities between amino acids that occur more commonly, or non-identical residues that have been shown to be frequently substituted for each other in closely related proteins. Nonidentical pairs of aligned amino acids which are unlikely substitutions are given negative scores. These scores were summated over the length of the peptide and those greater than 40 (cutoff of 40) were reported. In the second strategy, each peptide was broken into segments of seven amino acids, each segment overlapping the next by six residues. Each of these eight amino acid segments was compared with the library and all places where at least five amino acids matched were reported (Staden, 1988) .
Results

Anti-peptide antibodies in patients" sera
All peptides were tested against a single serum within a single plate. Three or four sera from HIV-seropositive individuals and a serum from a member of laboratory staff made up a batch within a single experiment. The values obtained for the within-batch control serum were subtracted from those obtained for the experimental sera and the cumulative values for the entire experimental series were plotted ( The same epitopes were recognized in a second series of experiments. This series was undertaken since it was not possible to include sera which were positive for each peptide on every plate and thus confirm that peptide was available for binding with antibody. In these experiments, all sera were tested within a single plate on which all wells had been coated with peptides of the same sequence. Sera raised in rats against the homologous and heterologous peptides were included on each plate and the number of sera from laboratory personnel was increased to 10. Thus, the presence of peptide on the plate was confirmed, either by its combining with human and/or rat antibodies in all cases except env 77. Env 77 is virtually insoluble in aqueous solution, as judged by u.v. absorption.
Inhibition studies
It is possible that peptides may bind antibody nonspecifically. The specificity of peptide-antibody interaction has been investigated by affinity purification of antibody using peptides and by inhibiting the interaction of solid-phase peptide and antibody using soluble peptide. The two peptides representing the principal epitopes of gp41 (env 61 and env 79) were used in inhibition experiments at the same concentration (10 ~tg/ml) which was used to coat the wells. Soluble env 61 inhibited antibody binding to solid-phase env 61, whereas env 63, env 67 and env 79, at the same concentration failed to do so. Soluble env 79 was not able to inhibit antibody binding to solid-phase env 79 (Fig. 2) Env 79 is sparingly soluble in aqueous solution and so the peptide was first dissolved in methanol and further diluted in phosphate buffer before repeating the experiment. However, there was no reduction in antibody binding to solid-phase env 79 in the presence of the same peptide dissolved in methanol/buffer (data not shown).
Affinity purification
The problem of non-specific binding of antibody by peptides was also excluded by separating antibodies of different specificities from each other on peptide affinity columns. However, the recovered antibody was not affinity-purified in the strictest sense because contamination with antibodies which were present in the original serum at high concentrations could also be demonstrated. Antibodies could be shown to be removed from serum following passage over a peptide affinity column and the specific antibody to be recovered when columns contained peptide but not when control columns without peptide were used ( Fig. 3 and 4) . However, the recovery of IgG was the same for both peptide and control columns. Thus, a total of 500 ng was recovered from the env 67 column and the same total from the control column although u.v. spectroscopy of the supernatant following incubation of Sepharose and peptide with cyanogen bromide revealed that 60% of the peptide had bound to the gel and this mass of peptide is enough to bind 45 mg of antibody. Similarly, a total of 20 ~tg was recovered from the env 60 column but 40 ~g was recovered from the control thiol-activated Sepharose column.
Columns were prepared by cyanogen bromide treatment with other peptides and Fig. 5 shows the antipeptide activity of antibodies affinity-purified against peptide env 61. Contamination became apparent when affinity purification was attempted with antibodies present at low concentrations in the original serum. Thus, antibodies affinity-purified over columns of peptides env 81, env 85 and env 86 were contaminated with env 61 activity. Similarly, peptide env 61-purified antibodies were contaminated with antibodies to env 17 (amino acids 161 to 175) and env 32 (amino acids 311 to 325) two of the major epitopes of gp 120 (data not shown). No purification was observed with env 79 peptide, probably because very little of this sparingly soluble peptide was available to bind to Sepharose.
Anti-peptide antibodies in normal human serum
Sera from laboratory personnel contained antibodies that recognized three of the six major epitopes in gp41 : env 61 (601 to 615), env 79 (781 to 795) and env 85 (841 to 855) (Fig. 1) . In addition, in the second series of experiments a further three peptides were recognized by a single serum among the 10 normal sera examined, in that they showed reactivity that was greater than the 
Computer searches
The presence of antibodies which recognize amir~o acid sequences of the gp41 molecule in sera from individuals who have not been infected with HIV-1 may be explained if similar sequences are present in other antigens to which humans are exposed. This idea was tested by searching protein libraries for amino acid sequences which were similar to those of the gp41 peptides. The first hypothesis tested was that sequences would be found in unrelated proteins for those amino acids in gp41 which bound antibody but not for those which failed to do so. This hypothesis was shown to be false (Table 2) . Thus, no sequences with a similarity score greater than 40 were found for the amino acids of peptide env 60 (which binds antibody from human sera) whereas sequences were found corresponding to peptides env 73 
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Rhinovirus 2 and env 76 which do not bind antibody. The statistical analysis of the individual scores was not pursued further as it is not relevant to the present hypothesis whether the sequence alignments occur by chance and no claim is being made for an evolutionary or functional relationship between the amino acid sequences showing similarity. However, the search did reveal that amino acid sequences similar to short segments of gp41 were widespread in proteins amongst different virus groups. Examination of the alignments revealed by this computer search (Fig. 6 ) led to the adoption of a strategy for a second computer search. Protein libraries were searched for stretches of seven amino acids (approximately the length of peptide to which antibody binds specifically) which show five or more identities with a segment of the gp41 molecule. Again, amino acid sequences with these properties were shown to be widespread amongst 
proteins from different virus groups which commonly infect man and antigens which are present in human vaccines (Tables 3 and 4) .
Discussion
The most significant result to emerge from these studies is that sera from laboratory personnel recognize the same epitopes in HIV-1 gp41 as sera from HIV-seropositive individuals. It is reasonable to conclude that these antibodies were produced in response to infections or other antigenic stimuli (e.g. vaccination) with agents other than HIV-1. Furthermore, similarities can be demonstrated over short sequences of amino acids, equivalent in size to the binding site of an antibody molecule, between the gp41 peptides and proteins from unrelated viruses and antigens used in inactivated vaccines. It is possible therefore that individuals may produce antibodies to an epitope on one virus which can recognize a similar epitope from an unrelated virus. There are two points to note. The amino acid sequences showing similarity occur by chance and do not represent any evolutionary relationship between the viruses involved. Secondly, similarities between the proteins of two infectious agents are not sufficient to render the amino acid sequence an epitope. Other factors must also be involved. However, it is suggested that the immunodominance within the epitopes of an antigen can be determined by the previous immunological experience of the host. This hypothesis can resolve the difficulties already observed with studies of the immune response to the HIV-1 gp41 antigen. Antibodies detected in assays using the whole molecule of gp41 show a subclass restriction in HIVinfected individuals. The restriction is to antibodies within the IgG1 and IgG3 subclasses and sometimes IgG4 (Sundqvist et al., 1986; Mathiesen et al., 1988) . However, there is a different subclass restriction for the immunodominant epitope and the E32 peptide (IWGCSGKLICTTAVPWNAS) in particular (Chiodi et al., 1989) which is recognized by the IgG1 and IgG2 subclasses. In addition, Mathiesen et al. (1989b) demonstrated that the amino acids within the epitope differed for the two subclasses: IgG1 recognized glycine (604), glycine (607) and lysine (608), whereas IgG2 recognized cysteine (605), glycine (607), lysine (608) and cysteine (611).
The interesting point to note in the present context is that the amino acids recognized by the IgG2 antibodies are identical for both HIV and rhinovirus 2 (Fig. 6) whereas one of the amino acids recognized by the IgG1 antibodies differs between the two proteins. It is conceivable therefore that the unusual subclass restriction to this region of the gp41 protein is a consequence of a distortion in the immunological memory produced by prior exposure of the patient to a similar epitope during rhinovirus infection.
The second principal epitope, corresponding to peptide env 79, may be an artefact as it was neither possible to inhibit binding of antibody to solid-phase antigen with soluble peptide, nor to absorb antibodies to peptide columns. However, these failures are more likely to be the result of technical limitations because the same problems have been experienced with other sparingly soluble peptides. For example, antisera raised to peptide env 6 (amino acids 51 to 65 of the external gpl20 envelope glycoprotein of HIV-1), a sparingly soluble peptide, bound specifically to solid-phase peptide env 6 and recombinant gpl20 but this binding could not be inhibited by soluble env 6. The specificity of antibody binding to solid-phase peptide env 6 was shown by the failure of these sera to bind to solid-phase peptides env 8 (amino acids 71 to 85) and env 9 (amino acids 81 to 95). Equally, antisera raised to these latter peptides did not bind to solid-phase peptide env 6. The probable cause for the failure of soluble peptide to inhibit antibody binding to solid-phase antigen is that it is just not possible to obtain these peptides at sufficient concentrations in aqueous solution. The necessary concentrations are relatively high. In experiments with rat antisera, concentrations of 2 to >50 ptg/ml of peptide were necessary to produce 50% inhibition of binding to solidphase antigen. This same lack of peptide solubility is probably also responsible for the failure to bind and recover antibody from peptide affinity purification columns. Very low yields (albeit enough for analytical purposes) were obtained from these columns even with soluble peptides which were known to be present in considerable excess. For example, 500 lag of antibody was recovered from a peptide env 67 column that had enough peptide present to bind 45 mg of specific antibody. All attempts to purify antibodies using similar columns, with sparingly soluble peptides from the gp 120 and gag p24 proteins of HIV-1, have given similar negative results.
Most of the antibody recovered from columns was not specific for the peptide conjugated to Sepharose. Three observations are relevant to this conclusion. First, although affinity-purified antibodies appear to be specific for the homologous peptide, they are frequently contaminated with antibodies of other specificities and the level of contamination is proportional to the concentration of antibody to these alternatives in the original serum. This phenomenon is more obvious when the contaminating antibodies are initially present at higher concentrations than the antibodies to be purified. Second, this contamination probably does not involve the binding of cross-reacting antibodies to peptide as equivalent quantities of antibody can be recovered from Sepharose columns which have been treated with cyanogen bromide irrespective of the presence or absence of peptide. However, there is a single exception to this observation. Antibodies to peptide env 64 were bound by and recovered from a peptide env 60 column and this occurrence was not seen with the control column run in parallel. In the single experiment reported in this communication, the level of non-specific binding of antibody to Sepharose was greater with thiol-activated gels in comparison with cyanogen bromide-treated material. Third, the effluent from the peptide columns shows increased activity against peptides in radioimmunoassays in comparison with the original serum. A possible mechanism for this occurrence is that material in serum binds non-specifically to plastic and interferes with antibody-peptide binding in radioimmunoassays. The removal of this interfering material, by nonspecifically binding to Sephadex, would then lead to an increase in the binding of antibody to solid-phase peptide.
No explanation can as yet be offered for the discrepancies between the observations reported in the present paper and those of Mathiesen et al. (1989a) . These authors demonstrated major epitopes within HIV-1 gp41 with peptides equivalent to env 59, env 60, env 61, env 63, env 66, env 80 and env 85 in the current series. The general pattern of epitopes from the two studies is similar but there are distinct shifts: env 63 to env 64, env 66 to env 67/68 and env 80 to env 79 or env 81.
An observation which may be significant in the pathogenesis of HIV-1 infections and in the development of a vaccine is that the putative neutralization epitopes within gp41 which have been reported in the literature, equivalent to peptides env 62, env 63, env 74 and env 75 (Kennedy et al., 1986; Ho et al., 1987; Evans et al., 1989) , fall in areas to which low levels of antibodies are produced in natural infections. Vaccination strategies will therefore be required which reverse the immunodominance of these epitopes.
